Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 17/20 | 0.43 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26141982 | 0.88 | GPR139 (0.35) | CRBNDDB1ALDH1A1 | |
| SCHEMBL26147530 | 0.81 | CRBN (0.43) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL21477243 | 0.80 | CRBN (0.51) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL20046865 | 0.79 | CRBN (0.47) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL21464665 | 0.77 | CRBN (0.38) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL24891103 | 0.75 | CRBN (0.47) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL20437025 | 0.75 | CRBN (0.47) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL29314085 | 0.75 | CRBN (0.47) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL25767825 | 0.74 | CRBN (0.48) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL22302005 | 0.73 | CRBN (0.43) | CRBNDDB1IKZF3ALDH1A1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | CRBN 5/4885DDB1 594/4885IKZF3 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.